Tomasz "Tommy" Stryjewski, MD

Tomasz "Tommy" Stryjewski, MD has a diverse and extensive work experience in the medical field. Tomasz "Tommy" currently holds the position of Vitreoretinal surgeon at Tallman Eye Associates since 2020. Prior to that, they served as the Chief Scientific Officer, Director, and Co-Founder of Pykus Therapeutics since its establishment in 2016.

In addition, Dr. Stryjewski worked as a Clinical Consultant for Aldeyra Therapeutics starting from January 2019, specializing in retinal diseases. Tomasz "Tommy" also served as the President and Co-Founder of Helio Vision, a biopharma company focused on developing therapies for rare proliferative diseases of the vitreous and retina. Helio Vision was subsequently acquired by Aldeyra Therapeutics in 2019.

Dr. Stryjewski has contributed their expertise as a Medical Advisor for Hubble Therapeutics from July 2020 to October 2021. Tomasz "Tommy" has also gained valuable experience in ophthalmology and vitreoretinal surgery at Massachusetts Eye and Ear from 2014 to 2019. Prior to that, they worked in internal medicine at Massachusetts General Hospital from 2013 to 2014.

Overall, Dr. Stryjewski's work experience reflects their commitment to advancing the field of ophthalmology, particularly in the areas of retinal diseases and vitreoretinal surgery.

Tomasz "Tommy" Stryjewski, MD, completed their education in a chronological order. From 2004 to 2007, they attended Louisiana State University, where they earned their Bachelor of Science degree in Biological Sciences. Following this, they pursued a medical career and enrolled in Harvard Medical School from 2008 to 2013. During this time, they obtained their Doctor of Medicine degree with honors. Simultaneously, from 2011 to 2013, they attended Harvard Kennedy School, where they obtained a Master's degree in Public Policy (MPP) with a focus on Public Policy.